These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17268929)

  • 1. Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8).
    Protopopescu C; Marcellin F; Spire B; Préau M; Verdon R; Peyramond D; Raffi F; Chêne G; Leport C; Carrieri MP
    Qual Life Res; 2007 May; 16(4):577-91. PubMed ID: 17268929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Outcome of HIV-infected patients after 5 years of antiretroviral therapy including a protease inhibitor: the Aproco/Copilote Cohort].
    Le Moing V; Chêne G; Spire B; Raffi F; Leport C;
    Presse Med; 2005 Jun; 34(10 Suppl):1S31-7. PubMed ID: 16025665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment.
    Préau M; Leport C; Salmon-Ceron D; Carrieri P; Portier H; Chene G; Spire B; Choutet P; Raffi F; Morin M
    AIDS Care; 2004 Jul; 16(5):649-61. PubMed ID: 15223534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of health-related quality of life among military HIV-infected individuals.
    Emuren L; Welles S; Macalino G; Evans AA; Polansky M; Ganesan A; Colombo RE; Agan BK;
    Qual Life Res; 2020 Jul; 29(7):1855-1869. PubMed ID: 32076926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The two-year impact of first generation protease inhibitor based antiretroviral therapy (PI-ART) on health-related quality of life.
    Eriksson LE; Bratt GA; Sandström E; Nordström G
    Health Qual Life Outcomes; 2005 May; 3():32. PubMed ID: 15871738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in French people living with HIV in 2003: results from the national ANRS-EN12-VESPA Study.
    Préau M; Marcellin F; Carrieri MP; Lert F; Obadia Y; Spire B;
    AIDS; 2007 Jan; 21 Suppl 1():S19-27. PubMed ID: 17159583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twelve-year mortality in HIV-infected patients receiving antiretroviral therapy: the role of social vulnerability. The ANRS CO8 APROCO-COPILOTE cohort.
    Protopopescu C; Raffi F; Spire B; Hardel L; Michelet C; Cheneau C; Le Moing V; Leport C; Carrieri MP;
    Antivir Ther; 2015; 20(7):763-72. PubMed ID: 25859625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life of people living with HIV followed up in hospitals in France: comparing trends and correlates between 2003 and 2011 (ANRS-VESPA and VESPA2 national surveys).
    Douab T; Marcellin F; Vilotitch A; Protopopescu C; Préau M; Suzan-Monti M; Sagaon-Teyssier L; Lert F; Carrieri MP; Dray-Spira R; Spire B;
    AIDS Care; 2014; 26 Suppl 1():S29-40. PubMed ID: 24731158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management.
    Jones M; Núñez M
    Curr Opin HIV AIDS; 2011 Nov; 6(6):546-52. PubMed ID: 22001896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life and survival among HIV-infected patients receiving highly active antiretroviral therapy: a study of patients in the AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort.
    de Boer-van der Kolk IM; Sprangers MA; Prins JM; Smit C; de Wolf F; Nieuwkerk PT
    Clin Infect Dis; 2010 Jan; 50(2):255-63. PubMed ID: 20014949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8).
    Carrieri MP; Villes V; Raffi F; Protopopescu C; Preau M; Salmon D; Taieb A; Lang JM; Verdon R; Chene G; Spire B;
    Int J Drug Policy; 2007 Aug; 18(4):288-95. PubMed ID: 17689377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Satisfaction with care in HIV-infected patients treated with long-term follow-up antiretroviral therapy: the role of social vulnerability.
    Préau M; Protopopescu C; Raffi F; Rey D; Chêne G; Marcellin F; Perronne C; Ragnaud JM; Leport C; Spire B;
    AIDS Care; 2012; 24(4):434-43. PubMed ID: 21999644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discussing HIV Status: Is It Easier After 10 Years of Antiretroviral Treatment? The ANRS CO8 APROCO-COPILOTE Cohort.
    Préau M; Laguette V; March L; Rabaud C; Hardel L; Protopopescu C; Granier P; Pierret J; Leport C; Raffi F;
    AIDS Behav; 2017 Jan; 21(1):118-128. PubMed ID: 26910336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of HIV care decentralization from the patient's perspective: health-related quality of life and perceived quality of services in Cameroon.
    Boyer S; Protopopescu C; Marcellin F; Carrieri MP; Koulla-Shiro S; Moatti JP; Spire B;
    Health Policy Plan; 2012 Jul; 27(4):301-15. PubMed ID: 21690123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of highly active antiretroviral therapy on health-related quality of life of adult recipients in Tanzania.
    Magafu MG; Moji K; Igumbor EU; Hashizume M; Mizota T; Komazawa O; Cai G; Yamamoto T
    AIDS Patient Care STDS; 2009 Jul; 23(7):563-70. PubMed ID: 19534603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Better quality of life with neuropsychological improvement on HAART.
    Parsons TD; Braaten AJ; Hall CD; Robertson KR
    Health Qual Life Outcomes; 2006 Feb; 4():11. PubMed ID: 16504114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
    de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
    J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.
    Chaix ML; Desquilbet L; Descamps D; Costagliola D; Deveau C; Galimand J; Goujard C; Signori-Schmuck A; Schneider V; Tamalet C; Pellegrin I; Wirden M; Masquelier B; Brun-Vezinet F; Rouzioux C; Meyer L; ;
    Antivir Ther; 2007; 12(8):1305-10. PubMed ID: 18240870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health related quality of life among both current and former injection drug users who are HIV-infected.
    Préau M; Protopopescu C; Spire B; Sobel A; Dellamonica P; Moatti JP; Carrieri MP;
    Drug Alcohol Depend; 2007 Jan; 86(2-3):175-82. PubMed ID: 16930864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.